Myat Han Soe1, Janet M Chiang1,2,3, Robert R Flavell4, Elham Khanafshar5, Laura Mendoza6, Hyunseok Kang7, Chienying Liu1. 1. Division of Endocrinology, Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA. 2. Division of Endocrinology, Department of Medicine, San Francisco VA Healthcare System, San Francisco, California 94121, USA. 3. Division of Endocrinology, Department of Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California 94110, USA. 4. Molecular Imaging and Therapeutics Clinical Section, Department of Radiology and Biomedical Imaging, University of California, and Department of Pharmaceutical Chemistry, San Francisco, California 94143, USA. 5. Division of Cytopathology, Department of Pathology, University of California, San Francisco, San Francisco, California 94143, USA. 6. College of Osteopathic Medicine, Touro University, Henderson, Nevada 89014, USA. 7. Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA.
Abstract
CONTEXT: Patients with radioactive iodine (RAI) refractory metastatic differentiated thyroid cancer (DTC) have poor prognosis. Early identification of RAI refractoriness may improve care. OBJECTIVE: This work aimed to characterize DTC patients with distant metastases (DM) at diagnosis who presented with non-iodine-avid disease. METHODS: Retrospective analyses of DTC patients with DM at diagnosis who presented between 2012 and 2020 were performed. Iodine uptake in DM was correlated with tumor histology and mutational profile. The difference in uptake between BRAFV600E-like (BVL) and RAS-like (RL) cancers based on insights from The Cancer Genome Atlas was evaluated. RESULTS: Among 78 patients, 48.7% had negative uptake in DM on the first posttherapy scan. Negative scans were highly prevalent in papillary thyroid carcinoma (PTC) with papillary architecture, PTC with BRAFV600E mutation, and PTC with both BRAFV600E and TERT promoter mutations (71.1%, 80.9%, and 100%, respectively). BVL and RL tumors exhibited distinct uptake patterns with negative scan prevalence of 76.9% and 14.3% (P = .005). Multivariate logistical regression confirmed high odds of negative uptake in BVL tumors with either BVL mutations or papillary architecture, 19.8 (95% CI, 2.72-144), and low odds of negative uptake in RL tumors with either RL mutations or follicular architecture, 0.048 (95% CI, 0.006-0.344), after adjusting for age, sex, race, RAI preparation method, bone metastases, and RAI dose. Patients with negative scans were significantly older (62.4 vs 47.0 years, P = .03). CONCLUSION: Among DTC patients with DM at diagnosis, non-iodine-avid disease is highly prevalent in patients with BVL cancers, particularly with BRAFV600E and TERT promoter mutations, and is associated with an older age. Better strategies are needed to improve RAI treatment response for these patients.
CONTEXT: Patients with radioactive iodine (RAI) refractory metastatic differentiated thyroid cancer (DTC) have poor prognosis. Early identification of RAI refractoriness may improve care. OBJECTIVE: This work aimed to characterize DTC patients with distant metastases (DM) at diagnosis who presented with non-iodine-avid disease. METHODS: Retrospective analyses of DTC patients with DM at diagnosis who presented between 2012 and 2020 were performed. Iodine uptake in DM was correlated with tumor histology and mutational profile. The difference in uptake between BRAFV600E-like (BVL) and RAS-like (RL) cancers based on insights from The Cancer Genome Atlas was evaluated. RESULTS: Among 78 patients, 48.7% had negative uptake in DM on the first posttherapy scan. Negative scans were highly prevalent in papillary thyroid carcinoma (PTC) with papillary architecture, PTC with BRAFV600E mutation, and PTC with both BRAFV600E and TERT promoter mutations (71.1%, 80.9%, and 100%, respectively). BVL and RL tumors exhibited distinct uptake patterns with negative scan prevalence of 76.9% and 14.3% (P = .005). Multivariate logistical regression confirmed high odds of negative uptake in BVL tumors with either BVL mutations or papillary architecture, 19.8 (95% CI, 2.72-144), and low odds of negative uptake in RL tumors with either RL mutations or follicular architecture, 0.048 (95% CI, 0.006-0.344), after adjusting for age, sex, race, RAI preparation method, bone metastases, and RAI dose. Patients with negative scans were significantly older (62.4 vs 47.0 years, P = .03). CONCLUSION: Among DTC patients with DM at diagnosis, non-iodine-avid disease is highly prevalent in patients with BVL cancers, particularly with BRAFV600E and TERT promoter mutations, and is associated with an older age. Better strategies are needed to improve RAI treatment response for these patients.
Authors: Ian Ganly; Iain J Nixon; Laura Y Wang; Frank L Palmer; Jocelyn C Migliacci; Ahmad Aniss; Mark Sywak; Antoine E Eskander; Jeremy L Freeman; Michael J Campbell; Wen T Shen; Fernanda Vaisman; Denise Momesso; Rossana Corbo; Mario Vaisman; Ashok Shaha; R Michael Tuttle; Jatin P Shah; Snehal G Patel Journal: Thyroid Date: 2015-08-12 Impact factor: 6.568
Authors: Tania Jaber; Steven G Waguespack; Maria E Cabanillas; Mohamed Elbanan; Thinh Vu; Ramona Dadu; Steven I Sherman; Moran Amit; Elmer B Santos; Mark Zafereo; Naifa L Busaidy Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958
Authors: Shinje Moon; Young Shin Song; Ye An Kim; Jung Ah Lim; Sun Wook Cho; Jae Hoon Moon; Seokyung Hahn; Do Joon Park; Young Joo Park Journal: Thyroid Date: 2017-03-07 Impact factor: 6.568
Authors: Jin Young Kwak; Eun-Kyung Kim; Jong-Kee Kim; Jeong-Hyun Han; Soon Won Hong; Tae Sung Park; Jong Rak Choi Journal: Head Neck Date: 2010-04 Impact factor: 3.147
Authors: Mahesh Saqcena; Luis Javier Leandro-Garcia; Jesper L V Maag; Vatche Tchekmedyian; Gnana P Krishnamoorthy; Prasanna P Tamarapu; Vera Tiedje; Vincent Reuter; Jeffrey A Knauf; Elisa de Stanchina; Bin Xu; Xiao-Hui Liao; Samuel Refetoff; Ronald Ghossein; Ping Chi; Alan L Ho; Richard P Koche; James A Fagin Journal: Cancer Discov Date: 2020-12-14 Impact factor: 39.397
Authors: C Rubino; F de Vathaire; M E Dottorini; P Hall; C Schvartz; J E Couette; M G Dondon; M T Abbas; C Langlois; M Schlumberger Journal: Br J Cancer Date: 2003-11-03 Impact factor: 7.640